# Magnesium Sulphate

```text
DRUG INFORMATION

  ADULT
    - Do not use Magnesium Sulfate in 5% Dextrose Injection in series connections. 2.2
      Recommended Dosage • The recommended loading dosage of Magnesium Sulfate in 5%
      Dextrose Injection in patients with eclampsia or preeclampsia is 4 to 6 grams over
      15 minutes followed by a recommended maintenance dosage of 1 to 2 grams every
      hour. • Obtain serum magnesium concentrations and assess clinical status to adjust
      the dosage.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'dosage and administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of Magnesium Sulfate in 5% Dextrose Injection have
      been established for the prevention of eclampsia in adolescents with preeclampsia
      and the treatment of seizures and prevention of recurrent seizures in adolescents
      with eclampsia. Dosing recommendation in pregnant adolescent patients are the same
      as for pregnant adult patients [see Dosage and Administration (2.2) ] .
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'pediatric use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - For patients with recurrent eclampsia, consider giving an additional 2 gram
      intravenous bolus. • For patients with eclampsia, therapy should continue until
      seizures cease. • The maximum recommended dosage is 30 to 40 grams of magnesium
      sulfate over 24 hours. • Administration of Magnesium Sulfate in 5% Dextrose
      Injection beyond 5 to 7 days is not recommended [see Warnings and Precautions
      (5.1) ] .
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'dosage and administration', retrieved 2026-08-29
    - Patients with severe renal impairment and/or a urine output less than 100 mL every
      4 hours are at greater risk for increased magnesium concentrations that may lead
      to toxicity ( 8.6 ) 8.1 Pregnancy Risk Summary Magnesium Sulfate in 5% Dextrose
      Injection is indicated in pregnant women for the prevention of eclampsia in women
      with preeclampsia and the treatment of seizures and prevention of recurrent
      seizures in women with eclampsia.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'use in specific populations', retrieved 2026-08-29
    - Dosing recommendation in pregnant adolescent patients are the same as for pregnant
      adult patients [see Dosage and Administration (2.2) ] . 8.6 Renal Impairment
      Magnesium is excreted solely by the kidneys.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'use in specific populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for magnesium sulfate (Magnesium
      Sulfate in Dextrose), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Magnesium Sulfate in 5% Dextrose Injection is indicated in pregnant
      women for the prevention of eclampsia in women with preeclampsia and the treatment
      of seizures and prevention of recurrent seizures in women with eclampsia.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'pregnancy', retrieved 2026-08-29
    - Fetal, neonatal, and maternal risks are discussed throughout the labeling.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'pregnancy', retrieved 2026-08-29
    - Clinical Considerations Labor or Delivery: Magnesium Sulfate in 5% Dextrose
      Injection is not approved for the treatment of pre-term labor.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Administration of Magnesium Sulfate in 5% Dextrose Injection to pregnant women
      longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the
      developing fetus, including skeletal demineralization and osteopenia [see Warnings
      and Precautions (5.1) ] . 8.2 Lactation The use of intravenous magnesium in
      pregnant women increases human milk magnesium concentrations only slightly and
      oral absorption of magnesium by the infant is poor.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'use in specific populations', retrieved 2026-08-29
    - The developmental and health benefits to the neonate of breastfeeding should be
      considered along with the mother's clinical need for Magnesium Sulfate in 5%
      Dextrose Injection and any potential adverse effects on the breastfed infant from
      Magnesium Sulfate in 5% Dextrose Injection or from the underlying maternal
      condition.
      Source: US FDA label for magnesium sulfate (Magnesium Sulfate in Dextrose),
      section 'use in specific populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)